Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CCR3 | P51677 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9373391 | 0.98 | SIGMAR1 (1.00) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL9521523 | 0.95 | SIGMAR1 (1.00) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL29048480 | 0.90 | SIGMAR1 (0.81) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL29048471 | 0.90 | SIGMAR1 (0.81) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL7402940 | 0.90 | SIGMAR1 (0.81) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL7372250 | 0.90 | SIGMAR1 (0.81) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| Fumaric Acid SCHEMBL1604005 | 0.89 | SIGMAR1 (0.80) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| Maleic Acid SCHEMBL1604001 | 0.89 | SIGMAR1 (0.80) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL8099058 | 0.89 | SIGMAR1 (0.82) | SIGMAR1MEN1TP53CYP1A2CYP3A4 | |
| SCHEMBL9374358 | 0.88 | SIGMAR1 (0.81) | SIGMAR1MEN1TP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263797-A1 | Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States | UNM RAINFOREST INNOVATIONS (US) | 2023-08-24 | — | — | US | claimed |
| WO-2016138135-A1 | SIGMA-1 RECEPTOR MODULATORS FOR TREATING HUNTINGTON'S DISEASE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-09-01 | — | — | WO | claimed |
| US-20120077844-A1 | USE OF PIPERIDINE DERIVATIVES AS DERMO-DECONTRACTING AGENTS | L'OREAL (FR) | 2012-03-29 | — | — | US | claimed |
| US-20100048624-A1 | USE OF PIPERIDINE DERIVATIVES AS DERMO-DECONTRACTING AGENTS | L'OREAL (FR) | 2010-02-25 | — | — | US | claimed |
| US-7629359-B2 | Use of piperidine derivatives as dermo-decontracting agents | L'OREAL (FR) | 2009-12-08 | — | — | US | claimed |
| EP-1765281-B1 | USE OF PIPERIDINE DERIVATIVES AS DERMO-DECONTRACTING AGENTS | OREAL (FR) | 2008-08-27 | — | — | EP | claimed |
| US-20070259915-A1 | Use of Piperidine Derivatives as Dermo-Decontracting Agents | L'OREAL (FR) | 2007-11-08 | — | — | US | claimed |
| EP-1765281-A1 | USE OF PIPERIDINE DERIVATIVES AS DERMO-DECONTRACTING AGENTS | L'OREAL (FR) | 2007-03-28 | — | — | EP | claimed |
| WO-2006003030-A1 | USE OF PIPERIDINE DERIVATIVES AS DERMO-DECONTRACTING AGENTS | L'OREAL (FR) | 2006-01-12 | — | — | WO | claimed |
| EP-0591426-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1994-04-13 | — | — | EP | claimed |
| EP-0507863-A4 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | — | 1993-07-07 | — | — | EP | claimed |
| WO-1993000313-A2 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-01-07 | — | — | WO | claimed |
| EP-0507863-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1992-10-14 | — | — | EP | claimed |
| WO-1991009594-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1991-07-11 | — | — | WO | claimed |
| US-20260083725-A1 | SIGMARI LIGAND FOR THE TREATMENT OF PANCREATIC CANCER | INST NAT SANTE RECH MED (FR) | 2026-03-26 | — | — | US | disclosed |
| EP-3364976-B1 | PIPERAZINYL NORBENZOMORPHAN COMPOUNDS AND METHODS FOR USING THE SAME | UNIV TEXAS (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250352561-A1 | COMPOSITIONS AND METHODS USING TETRAHYDROCANNABINOL AND COMPOSITIONS INCLUDING SAME FOR TREATING INDICATIONS INVOLVING INFLAMMATION | NAGY AURANGZEB NAFEES (US) | 2025-11-20 | — | — | US | disclosed |
| EP-1635805-A2 | SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECOVERY | Agy Therapeutics, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2006003030-A1 | USE OF PIPERIDINE DERIVATIVES AS DERMO-DECONTRACTING AGENTS | L'OREAL (FR) | 2006-01-12 | — | — | WO | disclosed |
| WO-2004110389-A2 | SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECOVERY | AGY THERAPEUTICS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077844-A1 | USE OF PIPERIDINE DERIVATIVES AS DERMO-DECONTRACTING AGENTS | PLOD3, CUTA, DSTN | SIGMAR1 4198/4885MEN1 1989/4885TP53 2006/4885 |
| US-20070259915-A1 | Use of Piperidine Derivatives as Dermo-Decontracting Agents | CUTA, PLOD3, PLIN5 | SIGMAR1 4247/4885MEN1 1996/4885TP53 2030/4885 |
| US-20100048624-A1 | USE OF PIPERIDINE DERIVATIVES AS DERMO-DECONTRACTING AGENTS | PLOD3, CUTA, DSTN | SIGMAR1 4198/4885MEN1 1989/4885TP53 2006/4885 |
| US-20260083725-A1 | SIGMARI LIGAND FOR THE TREATMENT OF PANCREATIC CANCER | SCTR, NGFR, SIGMAR1 | SIGMAR1 3/4885MEN1 3392/4885TP53 2066/4885 |
| US-20230263797-A1 | Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States | SARS1, SQSTM1, ATG4A | SIGMAR1 2480/4885MEN1 3325/4885TP53 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.